Program
nalmefene
Also written as “Nalmefene”, “Nalmefene hydrochloride” and “Nalmefene + 0.94% MgCl2”.
Its studies are mostly in Alcoholism · Opiate Overdose · Pruritus · Renal Insufficiency · Smoking Cessation, led by 7 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| H. Lundbeck | 60 open or running | phase 4since Jul 17, 2014 | Dec 18, 2008 | none ahead |
| Indivior Pharmaceuticals | 30 open or running | phase 1since Feb 15, 2021 | Feb 15, 2021 | none ahead |
| Knoa Pharma | 30 open or running | phase 4since Mar 15, 2023 | Mar 15, 2023 | none ahead |
| Otsuka | 30 open or running | phase 3since Feb 10, 2015 | Feb 10, 2015 | none ahead |
| Somaxon Pharmaceuticals | 20 open or running | phase 3since Aug 17, 2005 | Aug 17, 2005 | none ahead |
| Tharimmune | 21 open or running | phase 2since Dec 3, 2024 | Dec 27, 2023 | Mar 1, 2027phase 2 · NCT06733519 |
| Serentis | 10 open or running | phase 2since Feb 5, 2009 | Feb 5, 2009 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 2 studies since Aug 17, 2005.
- Dec 18, 2008H. Lundbeck's first studies: 3 phase 3 studies in AlcoholismNew to H. LundbeckH. Lundbeck · NCT00811941, NCT00811720, NCT00812461
- Feb 5, 2009Serentis's first study: phase 2 study in PruritusNew to SerentisSerentis · NCT00838708 · 62 enrolled · United States
- Aug 22, 2013Phase 1 study in Renal InsufficiencyH. Lundbeck · NCT01934166 · 32 enrolled · Germany
- Jul 17, 20142 phase 4 studies in AlcoholismH. Lundbeck · NCT02195817, NCT02197598
- Feb 10, 2015Otsuka's first studies: 2 phase 3 studies in AlcoholismNew to OtsukaOtsuka · NCT02382276, NCT02364947
- Jan 25, 2016Phase 1 study in AlcoholismOtsuka · NCT02679469 · 7 enrolled · Japan
- Feb 15, 2021Indivior Pharmaceuticals's first study: phase 1 study in PharmacokineticsNew to Indivior PharmaceuticalsIndivior Pharmaceuticals · NCT04759768 · 68 enrolled · United States
- Mar 30, 2021Phase 1 study in PharmacodynamicIndivior Pharmaceuticals · NCT04828005 · 84 enrolled · United States
- Jan 21, 2022Phase 1 study in Opiate OverdoseIndivior Pharmaceuticals · NCT05219669 · 24 enrolled · United States
- Mar 15, 2023Knoa Pharma's first study: phase 4 study in Opiate OverdoseNew to Knoa PharmaKnoa Pharma · NCT05808881
- Dec 27, 2023Tharimmune's first study: phase 1 study in HealthyNew to TharimmuneTharimmune · NCT06198686 · 20 enrolled · United States
- Dec 2, 2024Phase 1 study in Opiate OverdoseKnoa Pharma · NCT06719986 · 24 enrolled · United States
- Dec 3, 2024Phase 2 study in PruritusTharimmune · NCT06733519 · 40 planned
- Apr 15, 2026Phase 1 study in Opiate OverdoseKnoa Pharma · NCT07543276 · 13 enrolled · United States
Ahead
- Mar 1, 2027Primary completion: phase 2 study in PruritusTharimmune · NCT06733519
TargetBeta
“Mu opioid receptor antagonist; Delta opioid receptor antagonist; Kappa opioid receptor partial agonist”ChEMBL 37, by rule
Other programs on the same three targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Naltrexonerule | orexigen-therapeutics-inc | phase 4 | 42 |
| Nalbuphinerule | Trevi Therapeutics | phase 4 | 20 |
| cebranopadolrule | Tris Pharma | phase 3 | 18 |
Studies
All 20 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07543276Opiate Overdose · United States | 1 | Completed | Knoa Pharma | Apr 3, 2026 | 13 |
| NCT06733519Pruritus | 2 | Not yet recruiting | Tharimmune | Mar 1, 2027 | 40 |
| NCT06719986Opiate Overdose · United States | 1 | Completed | Knoa Pharma | Dec 23, 2022 | 24 |
| NCT06198686Healthy · United States | 1 | Completed | Tharimmune | Feb 11, 2024 | 20 |
| NCT05808881Opiate Overdose | 4 | Withdrawn | Knoa Pharma | May 2024 | 0 |
| NCT05219669Opiate Overdose · United States | 1 | Completed | Indivior Pharmaceuticals | Nov 19, 2021 | 24 |
| NCT04828005Pharmacodynamic · United States | 1 | Completed | Indivior Pharmaceuticals | Mar 14, 2022 | 84 |
| NCT04759768Pharmacokinetics · United States | 1 | Completed | Indivior Pharmaceuticals | May 17, 2021 | 68 |
| NCT02679469Alcoholism · Japan | 1 | Completed | Otsuka | Mar 2016 | 7 |
| NCT02382276Alcoholism · Japan | 3 | Completed | Otsuka | Jan 18, 2017 | 405 |
| NCT02364947Alcoholism · Japan | 3 | Completed | Otsuka | Jul 30, 2016 | 678 |
| NCT02197598Alcoholism · Germany | 4 | Completed | H. Lundbeck | Dec 2015 | 45 |
| NCT02195817Alcoholism · France, Germany, Spain and more | 4 | Terminated | H. Lundbeck | Feb 2016 | 378 |
| NCT01934166Renal Insufficiency · Germany | 1 | Completed | H. Lundbeck | Aug 2014 | 32 |
| NCT00838708Pruritus · United States | 2 | Completed | Serentis | Jul 2009 | 62 |
| NCT00812461Alcoholism · Belgium, Czech Republic, France and more | 3 | Completed | H. Lundbeck | Mar 2011 | 678 |
| NCT00811941Alcoholism · Czech Republic, Estonia, Hungary and more | 3 | Completed | H. Lundbeck | Nov 2010 | 665 |
| NCT00811720Alcoholism · Austria, Finland, Germany and more | 3 | Completed | H. Lundbeck | Oct 2010 | 598 |
| NCT00202696Smoking Cessation · United States | 2 | Completed | Somaxon Pharmaceuticals | Mar 2006 | 76 |
| NCT00132119Gambling | 3 | Completed | Somaxon Pharmaceuticals | Aug 2006 | 233 |
How it is read
Names in the registry
- “Nalmefene”, 5 entries
- “Nalmefene hydrochloride”, 3 entries
- “Nalmefene + 0.94% MgCl2”, 2 entries
- “Nalmefene Hydrochloride”, 2 entries
- “nalmefene”, 2 entries
Conditions, from the studies’ own filings
- Alcoholism, 8 studies
- Opiate Overdose, 4 studies
- Pruritus, 2 studies
- Renal Insufficiency, 1 study
- Smoking Cessation, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.